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Does Treatment of Bloody Diarrhea due to Shigella
dysenteriae Type 1 with Ampicillin Precipitate Hemolytic
Uremic Syndrome?
Diarrhea-associated hemolytic uremic syn-
drome (HUS), the most common cause of acute
renal failure in infancy and childhood, is often
associated with infection by organisms producing
Shiga toxin (ST) or Shiga-like toxin (SLT), mainly
verocytotoxin-producing Escherichia coli (VTEC
O157:H7) and Shigella dysenteriae type 1 (1,2).
Although antibiotics are believed to be essential
in treating shigellosis, treatment of S. dysenteriae
type 1 patients with antibiotics to which the or-
ganism is resistant has been considered a risk
factor for HUS (3,4).
Until 1993, HUS was rarely reported from
Saudi Arabia. Four cases of diarrhea-associated
HUS due to S. dysenteriae type 1 were identified
in 1989 (J. Hibbs and A. Mishkas, unpublished
report), and one case of HUS attributed to plasma
transfusion was documented in 1988 (5).
In May 1993, four dysentery-associated HUS
cases in two families were reported from north-
western Saudi Arabia (Tabuk). S. dysenteriae type
1 was isolated from the stool of each HUS patient.
The organism was also isolated from 6 of the other
10 members of the two families who had dysentery.
All isolates were resistant to trimethoprim-sul-
famethoxazole, chloramphenicol, tetracycline,
and ampicillin but sensitive to nalidixic acid. The
two families had just returned from a 1-week visit
to relatives in two neighboring villages in Gizan.
This densely populated region in southwestern
Saudi Arabia has about 1.2 million people living
in more than 4,000 villages; the population is
relatively poor and uneducated, and environ-
mental sanitation is generally inadequate.
We defined a case of HUS as any case of bloody
diarrhea (BD) that had all of the following: acute
renal failure (serum urea nitrogen, 18 mg/dL (or
6.3 mmol/L); or creatinine, 1.3 mg/dL (or 115
mmol/L)); thrombocytopenia (platelet count
130,000/mm3); and hemolytic anemia (hemoglo-
bin level less than 10 g/dL; or hematocrit less than
30%; or appearance of fragmented red cells on
direct microscopy). We standardized the treat-
ment of BD in the Gizan region as follows: No
antibiotics were given for treatment of BD at the
primary health care centers (PHCCs) before a
stool specimen was taken for culture and sensitiv-
ity testing. After reviewing the preliminary re-
sults, we either recommended use of nalidixic acid
for treatment of BD or were guided by the results
of the stool culture. This protocol was followed for
management of BD in the entire region.
Parasitologic, bacteriologic, and biochemical
tests and drug treatment regimens were obtained
for all patients admitted with BD or HUS to the
regional referral hospital or five district hospitals
in the outbreak area. BD cases were identified
through hospital admission records, visits to
PHCCs in the affected villages, interviews with
family members of the identified patients, and
school visits. We visited the houses of all HUS and
BD patients and interviewed family members to
ascertain which antibiotic was used to treat the
BD patients; mothers were shown bottles and
boxes of antibiotics and were asked to identify the
antibiotic used for treating the children with BD.
We identified 233 cases of BD occurring from
February through July 1993 among 79 families
scattered over 19 contiguous villages. Affected vil-
lages were predominantly in southern Gizan re-
gion near the Yemeni border. One hundred ninety
patients (81.5%) consulted PHCCs; of those, 97
(51%) were referred to hospitals, and 81 (43%)
were admitted. Thirty-four other BD patients
were admitted directly to hospitals (a total of 115
admissions). In nine BD cases patients did not
seek medical care including seven (3%) who used
traditional treatment (the Wicka plant). In 23
(10%) patients, 13 male and 10 female, BD devel-
oped into HUS. Four isolates of S. dysenteriae type
1 that showed the same antibiotic susceptibility
described earlier were obtained from four patients
with BD in different villages in the middle of the
outbreak. We used Cary-Blair transport medium
for transporting stool specimens collected before
antibiotic treatment from newly recognized pa-
tients with BD. However, community- and hospi-
tal-based interviews showed that the sequence of
symptoms was almost identical in all of the 233
BD cases: the condition started with colicky ab-
dominal pain and tenesmus (69%), followed by
watery diarrhea (60%), which rapidly became only
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Seven patients (3.0%) had rectal prolapse. S.
dysenteriae type 1 was not isolated from any of the
23 HUS patients; however, all stool specimens
were taken during antibiotic treatment.
Most BD cases (92.3%) were among Saudis; the
remaining 7.7% were among Yemeni patients. No
HUS case occurred among patients over 11 years
of age. The male/female ratio for both BD and HUS
was 1.3:1. Three boys and three girls with con-
firmed HUS died (case-fatality rate = 26.1%); none
of the patients with uncomplicated BD cases died.
Of the 23 HUS patients, 18 (78%) became ill
with the disease 2 to 14 days after hospital admis-
sion for uncomplicated BD. This compares with a
hospital admission rate of 40 (27%) of 147 for
children of the same age with BD from the same
villages (odds ratio = 9.6, 95% confidence interval
3.1-35). Five children, aged 8 to 16 months, got
HUS either before or on the day of hospital admis-
sion; all had received oral ampicillin at home for 5
to 7 days before their illness progressed to HUS.
In comparison, two of nine children of the same
age, with BD, who were not hospitalized, received
ampicillin at home (OR = infinite, p value = 0.02,
Fisher’s exact test).
Eighteen HUS cases occurred after the patients
were admitted to Samtah and Abu-Arish, two out
of five district hospitals. The demographic, clini-
cal, and laboratory profiles of BD and HUS cases
are shown in Table 1A-C. Six different antibiotics
were used in various combinations for treating BD
Places of hospitalization of BD and HUS cases      
Samtah Abu-Arish KFH Bysh Sabia 
No. of BD cases 43 42   13   9   8
No.  of  HUS  cases  8 14     -  -  1
a
Percentage of HUS cases 18.8 33.3   0   0 12.5
Median age in years: BD cases   4.0   5.0 7.0 4.0   4.0
Median age in years: HUS  cases  1.8  2.8  -  -  0.8
Mean (±SD) of duration (in days) 
between onset of symptoms and admission
to hospital:
  BD 3.8 (1.9) 5.5 (1.6) 4.5 (0.4) 3.7 3.9 (2.0)
  BD  complicated  with  HUS  5.2  (2.6) 4.5  (2.5)  -  -  -
  HUS diagnosed on admission 13.0 (2.8) 7.5 (0.7)   -   - 6.0 (0.0)
Laboratory test made on the day of
admission to the hospital
d     Non-HUS cases
HUS diagnosed 2-14 days
after admission to hospital
HUS diagnosed on
admission to hospital
Mean (N)
e SD Mean (N) SD Mean (N) SD
Serum creatinine 60 (16) 46 63 (3) 79 279 (3) 94
Blood urea nitrogin (BUN) 5.4 (23) 5.8 15.3 (3) 12.0 23.0 (3) 6.1
Serum sodium 129 (33) 9 137 (3) 4.6 127 (3) 14
Serum potassium 3.8 (47) 0.8 3.9 (7) 1.1 4.6 (5) 1.1
(Leukocytes [WBC] count) 14.2 (48) 6.0 34.0 (6) 24.7 41.2 (5) 18.8
Hemoglobin 11.3 (50) 2.3 12.0 (1) 1.5 6.8 (4) 2.5
Hematocrit 36.1 (13) 3.9 NA NA 15 (2) 7.1
Thrombocytes (platelets) 322 (5) 250 154 (1) - NA NA
(Body temperature on admis-
sion)
37.8
oC (75) 0.8 37.9
oC
(18)
0.8 37.9
oC (5) 0.9
Ampicillin 36.6 70.0 15.4 11.1 100.0
Metronidazole 14.6 55.0 7.7 0   100.0
Gentamicin 22.0 22.5 0   55.6 42.9
Nalidixic acid 70.7 57.5 61.5 66.7 0  
Claforan 2.4 20.0 0   11.1 0  
Amikacin 9.8 0 7.7 22.2 28.6
a Community case of HUS. 
b Percent of cases receiving the corresponding antibiotics. A patient may receive more than one antibiotic. Totals do not add up
to 100%. 
c This table does not include 5 cases diagnosed as HUS on admission and treated as cases of BD. 
d Creatinine in mg/dL, blood urea nitrogen in
mg/dL, sodium in mmol/L, potassium in mmol/L, WBC (white blood cell count) in thousands/mm, hemoglobin level in g/dL, hematocrit, platelets in
thousands/mm
3. Values shown are for children under 12 years of age only. 
e N = number of cases of BD diagnosed in the hospital. NA = not available. 
Table 1.
A. Profiles of children admitted to hospitals with bloody diarrhea (BD) or hemolytic uremic syndrome (HUS)
B. Percentage of 110 BD patients treated with antibiotics
b,c
C. Laboratory values of children hospitalized with BD or HUS
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with ampicillin prescribed alone or with other
antibiotics except nalidixic acid (Table 2), was
associated with development of HUS. However,
three BD patients who received nalidixic acid de-
veloped HUS. Of 12 BD patients (including eight
children under 12 years of age) who received no
antibiotic therapy, none got HUS.
These results support the implication from
Bangladesh and from a parallel investigation in
Saudi Arabia that inpatient antibiotic treatment
of children with dysentery due to S. dysenteriae
type 1 may precipitate HUS. We have extended
these observations to show the same association
for antibiotic treatment at home. Although Abu-
Arish and Samtah hospitals received similar num-
bers of BD patients, more HUS cases were
reported from Abu-Arish hospital, which used am-
picillin to treat patients with BD. The various
combinations of antibiotics used to treat BD pa-
tients could be explained by the presence of doc-
tors from parts of the world that have different
prescription practices. Three BD patients got HUS
despite the use of nalidixic acid. Resistance to
nalidixic acid among S. dysenteriae isolates was
reported from Bangladesh; resistance increased
from 2.1% in 1986 to 57.9% in 1990 (6).
We recommend a laboratory-based surveillance
system to identify and promptly contain emerging
outbreaks. Physicians need to be informed con-
tinuously about emerging resistant strains of bac-
teria and be cautious when using antibiotics to
treat patients with dysentery unless the causative
organism and the resistance pattern have been
identified. Parents of children with BD need to be
educated to take their children to the nearest
health facility as soon as possible.
S. dysenteriae is a delicate bacterium that does
not withstand adverse conditions (e.g., heat and
dryness); prompt plating, preferably at bedside, is
recommended (7). Failure to isolate S. dysenteriae
type 1 from dysenteric stool specimens during this
outbreak could be attributed to delayed plating of
specimens, lack of appropriate transport media,
Table 2. Risk of developing hemolytic uremic syndrome (HUS) by antibiotic combination used for treatment of bloody diarrhea
(BD), Gizan, Saudi Arabia, 1993
Antibiotic combination group Antibiotic combinations
    Dysentery patients
         D e v e l o p i n g
 Total (N = 110)      HUS (N =
18)
BD cases
admitted to
Samtah and Abu-
Arish Hospitals  HUS rate (%) Risk ratio
95% 
confidence  
Interval
a
Nalidixic acid with or
 without  other 
  antibiotics, but no 
 ampicillan
b
N(3/23), N+G (0/7)
G+N+C+A (0/1), M+N
(0/1), M+N+C (0/2),
N+C (0/4)
41  3 28  7.3  1 0.23–4.34
No antibiotic No antibiotic (0/12) 12   0   6   0.0   NC
c p value = 0.629
d
Antibiotic other than
 nalidixic  acid  or 
 ampicillin
A (0/1), C (1/0), G (0/1).
M+G (0/1)
 4  1  4 25.0  1.58 0.22–11.58
e
Ampicillin with or
 without  other
  antibiotics but no
 nalidixic  acid
28 10 19 35.7  6.90 0.98–48.68
   Ampicillin  only   P  (3/3)    6    3    5 50.0  6.11 1.31–28.54
      Ampicillin with other
    antibiotics  but  no
    nalidixic  acid
    P+G (1/2), P+M (2/3),
    P+M+A (0/2), P+M+C 
   ( 1 / 0 )   P + M + G   ( 3 / 8 )
  22    7   14 31.8 10.50 0.54–205.39
Ampicillin and
  nalidixic acid with or 
 without  other 
 antibiotics
P+M+G+N (1/1), P+M+N
0/10), P+M+N+C (1/0).
P+N (1/8), P+N+A (1/2)
25  4 24 16.0  1.77 0.31–10.21
HUS rate (%) calculated from total number of BD in the five district hospitals using corresponding antibiotic .
a Mantel-Haenszel weighted relative risk adjusted to
hospital (Epi Info, version 6.02). Analysis restricted for data from Samtah and Abu-Arish hospitals. HUS was not reported from the other three district hospitals.
b Reference group. A = amikacin, C = claforan, g = gentamicin, N = nalidixic acid, M = metronidazole, P = ampicillin. Numbers between parentheses in the second
column (antibiotic combination) indicate the (number of patients with HUS who took the corresponding antibiotic combination number or patients with BD who took
the same antibiotic combination but did not develop HUS in the five district hospitals). 
c NC = not calculated. 
d One-tailed Fisher’s exact test. 
e Adjusted Mantel-Haenszel
relative risk could not be calculated.
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mens were obtained. Even with direct inoculation
of stool specimens in pediatric wards, HUS re-
sulted in a low yield of S. dysenteriae type 1 (8,9).
Treatment of BD due to S. dysenteriae type 1
with ampicillin may precipitate HUS. It would be
valuable to retrospectively examine this associa-
tion in other countries where both dysentery due
to S. dysenteriae type 1 and HUS are reported. 
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